12/21/2022 7:25:50 PM
Natera Says Supports Updated ISHLT Guidelines For Care Of Heart Transplant Patients
12/6/2022 5:32:40 AM
Natera Publishes Clinical Experience Study In Twin Pregnancies Supporting Excellent Performance Of Panorama NIPT
11/15/2022 11:25:38 PM
Natera Announces Pricing Of Follow-On Offering Of 11.43 Mln Shares At $35/Shr
8/11/2022 7:33:24 AM
Natera Announces Enrollment Completion For RenaCARE Study
5/24/2022 8:11:20 AM
Natera Appoints Minetta Liu As Chief Medical Officer Of Oncology
4/26/2022 7:37:01 AM
Natera : RenaCARE Study On Chronic Kidney Disease Expected To Be Fully Enrolled By End Of Q2
4/13/2022 7:34:50 AM
Natera:Clinical Validation Of Prospera Heart Test Shows Outstanding Performance In Assessing Heart Transplant Rejection
4/11/2022 7:35:11 AM
Natera To Present Data From BEATRICE And I-SPY2 Trials In Early-Stage TNBC And HR+/HER2- Breast Cancer
3/22/2022 7:39:03 AM
Natera : Data In Simultaneous Pancreas-Kidney Transplantation Further Shows Value Of Prospera Dd-cfDNA Technology
3/21/2022 7:38:36 AM
Natera Updates Signatera MRD Data;analysis Shows 75% Detection Of Recurrence With Single Blood Draw 4 Weeks Post Surgery
3/15/2022 1:21:05 AM
Jury In Delaware District Court Finds CareDx And Natera Engaged In False Advertising
3/14/2022 7:12:01 AM
Natera Executives And Board Agree To Take Company Stock Instead Of Their Salaries And Retainers For Remainder Of 2022